Pfizer’s BioNTech Divestment Sends Shockwaves Through Markets

The formal dissolution of one of biotech’s most prominent partnerships has rattled investors, with Pfizer’s complete exit from its BioNTech stake triggering immediate market repercussions. This symbolic separation raises fundamental questions about the German firm’s ability to sustain momentum without its powerful American ally.

While Pfizer liquidated its entire remaining position in BioNTech—a transaction potentially exceeding $500 million—another institutional player demonstrated remarkable confidence. Allworth Financial LP dramatically increased its stake during the second quarter, expanding its position by an astonishing 1,170 percent. This divergence in investment strategy highlights the polarized market sentiment regarding BioNTech’s future prospects. The announcement prompted an immediate pre-market decline of approximately five percent Read more...